Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Cardiology Journal
MENU
Shortcuts Submit an article CJ Guide for Authors (new) Recent articles Special collections Ahead Of Print APIS-S Online Calculator OCT Contrast Calculator Reviewers 2022

open access

Vol 30, No 5 (2023)
Original Article
Submitted: 2021-03-15
Accepted: 2021-07-08
Published online: 2021-08-02
View PDF Download PDF file View HTML Supp./Additional Files [3]
Get Citation

The comparison of Kardia Mobile and Hartmann Veroval 2 in 1 in detecting first diagnosed atrial fibrillation

Tomasz Zaprutko1, Joanna Zaprutko2, Józefina Sprawka3, Monika Pogodzińska3, Michał Michalak4, Anna Paczkowska1, Krzysztof Kus2, Elżbieta Nowakowska5, Artur Baszko2
DOI: 10.5603/CJ.a2021.0083
·
Pubmed: 34355779
·
Cardiol J 2023;30(5):762-770.
Affiliations
  1. Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Poznan, Poland
  2. Second Department of Cardiology, Poznan University of Medical Sciences, HCP Medical Center, Poznan, Poland
  3. Student Scientific Society, Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Poznan, Poland
  4. Department of Computer Sciences and Statistics, Poznan University of Medical Sciences, Poznan, Poland
  5. Department of Pharmacology and Toxicology, University of Zielona Gora, Poland

open access

Vol 30, No 5 (2023)
Original articles — Clinical cardiology
Submitted: 2021-03-15
Accepted: 2021-07-08
Published online: 2021-08-02

Abstract

Background: Atrial fibrillation (AF) is the leading cause of stroke. The European Society of Cardiology
(ESC) advises opportunistic AF screening among patients aged ≥ 65 years. Considering this, the
aim herein, was compare the feasibility of two different systems of smartphone-based electrocardiogram
(ECG) recordings to identify AF among those without a previous arrhythmia history.
Methods: Prospective AF screening was conducted at six pharmacies using Kardia Mobile and
Hartmann Veroval 2 in 1. A single-lead ECG was acquired by the placement of fingers on the pads.
A cardiologist evaluated findings from both devices.
Results: Atrial fibrillation was identified in 3.60% and previously unknown AF was detected in 1.92%
of the study participants. Sensitivity and specificity of the Kardia application in detecting AF were
66.7% (95% confidence interval [CI] 38.4–88.2%) and 98.5% (95% CI 96.7–99.5%), and for Veroval
10.0% (95% CI 0.23–44.5%) and 94.96% (95% CI 92.15–96.98%), accordingly. Inter-rater agreement
was k = 0.088 (95% CI 1.59–16.1%).
Conclusions: Mobile devices can detect AF, but each finding must be verified by a professional. The
Kardia application appeared to be more user-friendly than Veroval. Cardiovascular screening using
mobile devices is feasible at pharmacies. Hence it might be considered for routine use.

Abstract

Background: Atrial fibrillation (AF) is the leading cause of stroke. The European Society of Cardiology
(ESC) advises opportunistic AF screening among patients aged ≥ 65 years. Considering this, the
aim herein, was compare the feasibility of two different systems of smartphone-based electrocardiogram
(ECG) recordings to identify AF among those without a previous arrhythmia history.
Methods: Prospective AF screening was conducted at six pharmacies using Kardia Mobile and
Hartmann Veroval 2 in 1. A single-lead ECG was acquired by the placement of fingers on the pads.
A cardiologist evaluated findings from both devices.
Results: Atrial fibrillation was identified in 3.60% and previously unknown AF was detected in 1.92%
of the study participants. Sensitivity and specificity of the Kardia application in detecting AF were
66.7% (95% confidence interval [CI] 38.4–88.2%) and 98.5% (95% CI 96.7–99.5%), and for Veroval
10.0% (95% CI 0.23–44.5%) and 94.96% (95% CI 92.15–96.98%), accordingly. Inter-rater agreement
was k = 0.088 (95% CI 1.59–16.1%).
Conclusions: Mobile devices can detect AF, but each finding must be verified by a professional. The
Kardia application appeared to be more user-friendly than Veroval. Cardiovascular screening using
mobile devices is feasible at pharmacies. Hence it might be considered for routine use.

Full Text:

View PDF Download PDF file View HTML Supp./Additional Files [3]
Get Citation

Keywords

atrial fibrillation, mobile devices, screening, pharmacies, new technologies

Supp./Additional Files (3)
Supplementary Figure 1. The example of Kardia “tachycardia” finding.
Download
67KB
Supplementary Figure 2. The example of Veroval “non-interpretable” finding.
View
121KB
Supplementary Figure 3. The example of Veroval “rhythm wave” finding.
View
139KB
About this article
Title

The comparison of Kardia Mobile and Hartmann Veroval 2 in 1 in detecting first diagnosed atrial fibrillation

Journal

Cardiology Journal

Issue

Vol 30, No 5 (2023)

Article type

Original Article

Pages

762-770

Published online

2021-08-02

Page views

2250

Article views/downloads

900

DOI

10.5603/CJ.a2021.0083

Pubmed

34355779

Bibliographic record

Cardiol J 2023;30(5):762-770.

Keywords

atrial fibrillation
mobile devices
screening
pharmacies
new technologies

Authors

Tomasz Zaprutko
Joanna Zaprutko
Józefina Sprawka
Monika Pogodzińska
Michał Michalak
Anna Paczkowska
Krzysztof Kus
Elżbieta Nowakowska
Artur Baszko

References (43)
  1. Tison GH, Sanchez JM, Ballinger B, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 2018; 3(5): 409–416.
    CrossRefPubMed
  2. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018; 72(3): e13070.
    CrossRefPubMed
  3. Yan BP, Lai WHS, Chan CKY, et al. Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. J Am Heart Assoc. 2018; 7(8).
    CrossRefPubMed
  4. Jacobs MS, Kaasenbrood F, Postma MJ, et al. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018; 20(1): 12–18.
    CrossRefPubMed
  5. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006; 9(5): 348–356.
    CrossRefPubMed
  6. White RD, Flaker G. Smartphone-based Arrhythmia Detection: Should we encourage patients to use the ECG in their pocket? J Atr Fibrillation. 2017; 9(6): 1605.
    CrossRefPubMed
  7. Chan PH, Wong CK, Poh YC, et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc. 2016; 5(7).
    CrossRefPubMed
  8. Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care. 2010; 16(7): 525–533.
    PubMed
  9. Yoneda Y, Okuda S, Hamada R, et al. Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers. Health Policy. 2005; 73(2): 202–211.
    CrossRefPubMed
  10. Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–220.
    CrossRefPubMed
  11. Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace. 2015; 17(7): 1023–1029.
    CrossRefPubMed
  12. Miotla P, Olejniczak P, Futyma K, et al. Can intradetrusor onabotulinumtoxina injections alter heart function in patients with cardiac arrhythmia? J Clin Med. 2018; 7(9): 263.
    CrossRefPubMed
  13. Giebel GD, Gissel C. Accuracy of mHealth Devices for Atrial Fibrillation Screening: Systematic Review. JMIR Mhealth Uhealth. 2019; 7(6): e13641.
    CrossRefPubMed
  14. Proietti M, Farcomeni A, Goethals P, et al. Belgian Heart Rhythm Week Investigators. Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. Eur J Prev Cardiol. 2019; 26(9): 964–972.
    CrossRefPubMed
  15. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020.
  16. Chan PH, Wong CK, Poh YC, et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc. 2016; 5(7): e003428.
    CrossRefPubMed
  17. Zaprutko T, Zaprutko J, Baszko A, et al. Feasibility of atrial fibrillation screening with mobile health technologies at pharmacies. J Cardiovasc Pharmacol Ther. 2020; 25(2): 142–151.
    CrossRefPubMed
  18. Godin R, Baranchuk A, Guerra P, et al. Screening for atrial fibrillation via mobile ECG in Canadian primary care practice: a feasibility evaluation. Can J Cardiol. 2018; 34(10): S104.
    CrossRef
  19. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014; 111(6): 1167–1176.
    CrossRefPubMed
  20. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm. 2015; 37(6): 1111–1120.
    CrossRefPubMed
  21. Evans GF, Shirk A, Muturi P, et al. Feasibility of using mobile ECG recording technology to detect atrial fibrillation in low-resource settings. Glob Heart. 2017; 12(4): 285–289.
    CrossRefPubMed
  22. Lau JK, Lowres N, Neubeck L, et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol. 2013; 165(1): 193–194.
    CrossRefPubMed
  23. Hartmann-BP750X-Manual.pdf [Internet]. https://medaval.ie/docs/manuals/Hartmann-BP750X-Manual.pdf (cited 5 December 2019).
  24. AliveCor | FDA-cleared EKG at your fingertips. [Internet]. AliveCor, Inc. https://store.alivecor.com/ (cited 17 January 2019).
  25. Kardia now detecting Bradycardia and Tachycardia | AliveCor [Internet]. https://www.alivecor.com/blog/news/kardia_now_detecting_bradycardia_and_tachycardia/ (cited 18 February 2020).
  26. McHugh M. Interrater reliability: the kappa statistic. Biochemia Medica. 2012; 22(3): 276–282.
    CrossRef
  27. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation. 2017; 136(19): 1784–1794.
    CrossRefPubMed
  28. Ramkumar S, Nerlekar N, D'Souza D, et al. Atrial fibrillation detection using single lead portable electrocardiographic monitoring: a systematic review and meta-analysis. BMJ Open. 2018; 8(9): e024178.
    CrossRefPubMed
  29. Koshy AN, Sajeev JK, Negishi K, et al. Accuracy of blinded clinician interpretation of single-lead smartphone electrocardiograms and a proposed clinical workflow. Am Heart J. 2018; 205: 149–153.
    CrossRefPubMed
  30. Desteghe L, Raymaekers Z, Lutin M, et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Europace. 2017; 19(1): 29–39.
    CrossRefPubMed
  31. William AD, Kanbour M, Callahan T, et al. Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: The iREAD Study. Heart Rhythm. 2018; 15(10): 1561–1565.
    CrossRefPubMed
  32. Selder JL, Breukel L, Blok S, et al. A mobile one-lead ECG device incorporated in a symptom-driven remote arrhythmia monitoring program. The first 5,982 Hartwacht ECGs. Neth Heart J. 2019; 27(1): 38–45.
    CrossRefPubMed
  33. Lane DA, McMahon N, Gibson J, et al. Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. Europace. 2020 [Epub ahead of print].
    CrossRefPubMed
  34. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007; 335(7616): 380.
    CrossRefPubMed
  35. Coppetti T, Brauchlin A, Müggler S, et al. Accuracy of smartphone apps for heart rate measurement. Eur J Prev Cardiol. 2017; 24(12): 1287–1293.
    CrossRefPubMed
  36. Koshy AN, Sajeev JK, Nerlekar N, et al. Smart watches for heart rate assessment in atrial arrhythmias. Int J Cardiol. 2018; 266: 124–127.
    CrossRefPubMed
  37. Koshy AN, Sajeev JK, Teh AW. Letter by koshy et al regarding article, "Assessment of remote heart rhythm sampling using the alivecor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study". Circulation. 2018; 137(20): 2191–2192.
    CrossRefPubMed
  38. Tassie E, Scotland G, Neilson AR. A model based cost-effectiveness analysis of opportunistic screening for identifying atrial fibrillation with a single lead handheld electrocardiogram monitor in general practices in Scotland. HERU.
  39. Young JD, Badowski ME. Telehealth: increasing access to high quality care by expanding the role of technology in correctional medicine. J Clin Med. 2017; 6(2).
    CrossRefPubMed
  40. Zaprutko T, Kopciuch D, Kus K, et al. Affordability of medicines in the European Union. PLoS One. 2017; 12(2): e0172753.
    CrossRefPubMed
  41. Zaprutko T, Hromovyk B, Lesyk R, et al. Pharmacies for the pharmacists — Ukrainian Fears and Polish Experiences. Scientia Pharmaceutica. 2020; 88(1): 7.
    CrossRef
  42. Hickey KT, Biviano AB, Garan H, et al. Evaluating the Utility of mHealth ECG Heart Monitoring for the Detection and Management of Atrial Fibrillation in Clinical Practice. J Atr Fibrillation. 2017; 9(5): 1546.
    CrossRefPubMed
  43. Delgoshaei B, Mobinizadeh M, Mojdekar R, et al. Telemedicine: A systematic review of economic evaluations. Med J Islam Repub Iran. 2017; 31: 113.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl